Analyse de l’activité de chimiothérapie anticancéreuse en hospitalisation à domicile à partir du PMSI-HAD (notice n° 1578735)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04900cam a2200349 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20251228045517.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Couillerot-Peyrondet |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Analyse de l’activité de chimiothérapie anticancéreuse en hospitalisation à domicile à partir du PMSI-HAD |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2016.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 40 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Objectif : Les pouvoirs publics souhaitent développer l’hospitalisation à domicile (HAD) et s’interrogent sur la place de la chimiothérapie en HAD. L’analyse du PMSI-HAD a permis de la caractériser et d’identifier les modes de prise en charge, selon les patients et les pathologies. Méthodes : Dans le PMSI-HAD 2012, les séjours avec au moins une sous-séquence renseignée en mode de prise en charge principal (MPP) ou associé (MPA) de chimiothérapie anticancéreuse ont été sélectionnés. Les molécules administrées, inscrites sur la liste en sus sont identifiables et ont été recherchées. Résultats : 16 975 séjours d’HAD comportaient au moins une activité de chimiothérapie anticancéreuse. Pour 85 % d’entre eux, la chimiothérapie était l’unique mode de prise en charge ; pour 7 %, elle était associée à une surveillance post-chimiothérapie. Lorsque la chimiothérapie correspondait au MPP, la prise en charge de la douleur était renseignée en MPA dans 4 % des cas. Les diagnostics les plus fréquents étaient les hémopathies (61 %) et les tumeurs du sein (14 %). Les séjours comportant une molécule inscrite sur la liste en sus (55 %) concernaient des patients plus âgés et davantage d’hommes. L’activité était concentrée dans quelques établissements et dans quatre régions. 73 % des hémopathies malignes étaient traitées par une molécule en sus principalement par bortézomib et azacitidine. 41 % des tumeurs du sein étaient traitées avec une molécule en sus, principalement par trastuzumab. Conclusion : L’activité de chimiothérapie anticancéreuse en HAD était hétérogène sur le territoire et concentrée dans quelques établissements ; 10 % des établissements concentraient 90 % des séjours. Cependant les pathologies traitées étaient homogènes. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Place of hospital at home cancer chemotherapy: Analysis of 2012 PMSI-HAD data Background: French public authorities wish to develop Hospital at Home (HaH) and have raised the question of the place of chemotherapy in this type of healthcare. A PMSI-HAD analysis was conducted in order to characterize HaH chemotherapy and identify the healthcare organisation according to the patients and the diseases. Methods: Based on the 2012 PMSI HAD, HaH stays with at least one subsequence principal or associated cancer chemotherapy category were selected. Only drugs, not included in the hospital billing, were studied. Results: 16,975 HaH stays included at least one cancer chemotherapy. In 85% of cases, chemotherapy was the only category; 7% were associated with post-chemotherapy monitoring. When chemotherapy was the principal category, pain care was selected as the associated category in 4% of cases. When the associated category was chemotherapy, the main categories were palliative care (60%) or pain care (15%). The most common diagnoses were haematological malignancies (61%) and breast cancer (14%). HaH stays with drugs not included in the hospital billing (55%) corresponded to older patients with a male predominance. Home chemotherapy was concentrated in a few HaH structures, and in four regions. Haematological malignancies were mostly treated by drugs not included in the hospital billing (73% of stays), mostly bortezomib and azacitidine. 41% of breast cancers were treated with drugs not included in the hospital billing, mainly trastuzumab. Conclusion: HaH cancer chemotherapy activity was not evenly distributed throughout France, but was concentrated in few hospitals; 10% of hospitals accounted for 90% of home chemotherapy. However, the diseases treated were homogeneous. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | agents antinéoplasiques |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | chimiothérapie anticancéreuse |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Haute Autorité de santé |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hospitalisation à domicile |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | programme de médicalisation des systèmes d’information (PMSI) |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | systèmes informatisés de dossiers médicaux (PMSI) |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | antineoplastic agents |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer chemotherapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | home care services |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hospital-based |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Medical Information Programme |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | medical records systems computerized |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Leclerc, Stéphanie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hirtzlin, Isabelle |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rumeau-Pichon, Catherine |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Santé Publique | 28 | 3 | 2016-06-08 | p. 341-352 | 0995-3914 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/revue-sante-publique-2016-3-page-341?lang=fr&redirect-ssocas=7080">https://stm.cairn.info/revue-sante-publique-2016-3-page-341?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux